Privia Health Group

Aging US Demographics And AI Adoption Will Transform Healthcare Services

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

10 Sep 24

Updated

27 Nov 25

Views

74

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

17.1%

7D

2.3%

Loading

1Y

17.1%

7D

2.3%

You can edit this narrative until Nov 28 9:05 PM. Then, changes will post as Updates.

Author's Valuation

US$31.1121.7% undervalued

AnalystConsensusTarget Fair Value

Shared on 27 Nov 25

Fair value Increased 0.70%

PRVA: Future Shared Savings Results Will Drive Earnings Upside Through 2025

Privia Health Group's analyst fair value estimate has increased slightly to $31.11 from $30.89, as analysts cite improved revenue growth projections and stronger 2025 EBITDA guidance following favorable Medicare Shared Savings Program results. Analyst Commentary Analysts provided updated perspectives on Privia Health Group following recent announcements and improved financial guidance.

Shared on 10 Nov 25

Fair value Increased 2.45%

PRVA: Future Shared Savings Performance Will Support Profitability And Earnings Momentum

Analysts have raised their price target for Privia Health Group to approximately $30.89 from $30.15 per share, citing improved EBITDA guidance as a result of continued strong performance in shared savings programs. Analyst Commentary Recent analyst opinions reflect both confidence and caution regarding Privia Health Group's prospects.

Shared on 30 Apr 25

Fair value Increased 0.50%

Shared on 23 Apr 25

Fair value Decreased 0.13%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 1.28%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 0.60%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 2.20%

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 0.17%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 11 Mar 25

Fair value Decreased 2.64%

AnalystConsensusTarget has decreased revenue growth from 12.1% to 10.1%, decreased profit margin from 3.0% to 2.6% and increased future PE multiple from 58.8x to 72.1x.

AnalystConsensusTarget Fair Value

US$31.11

21.7% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

10.58%

Healthcare Services revenue growth rate

0.23%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.96%

Calculation

US$81.68m

Earnings '28

x

60.57x

PE Ratio '28

=

US$4.95b

Market Cap '28

US$4.95b

Market Cap '28

/

130.78m

No. shares '28

=

US$37.83

Share Price '28

US$37.83 Share Price '28

Discounted to 2025 @ 6.96% p.a.

=

US$30.92

Fair Value '25